TCM
NRIX icon

TD Capital Management’s Nurix Therapeutics NRIX Stock Holding History

TD Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$238 – 754
2025
Q1 		$238 Buy
+20
New +$335 ﹤0.01% 656

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TD Capital Management's NRIX Position: Q2 2025 in Review

TD Capital Management sold out of Nurix Therapeutics (NRIX) in Q2 2025, closing a stake of 20 shares — an estimated $238 sold.

TD Capital Management first reported a position in NRIX in Q1 2025 and held it in 1 quarter. The position peaked at $238 in Q1 2025. 163 funds tracked by Wall St. Rank hold NRIX as of Q2 2025.

  • TD Capital Management reported no remaining Nurix Therapeutics position as of Q2 2025 after selling out during the quarter.
  • TD Capital Management sold 20 Nurix Therapeutics shares in Q2 2025, an estimated $238.
  • TD Capital Management first reported a position in Nurix Therapeutics in Q1 2025 and held it in 1 quarter.
  • TD Capital Management's Nurix Therapeutics position peaked at $238 in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2025.

Based on TD Capital Management's 13F filing for Q2 2025, filed 8 Aug 2025.